Common genetic variants associated with disease from genome-wide association studies are mutually exclusive in prostate cancer and rheumatoid arthritis

BJU International

Volumn 111, Issue 7, 2013, Pages 1148-1155

  Orozco, Gisela ^a   Goh, Chee L ^b   Al Olama, Ali Amin ^c   Benlloch Garcia, Sara ^c   Govindasami, Koveela ^b   Guy, Michelle ^b   Muir, Kenneth R ^d   Giles, Graham G ^e,f   Severi, Gianluca ^e,f   Neal, David E ^g,h   Hamdy, Freddie C ^i,j   Donovan, Jenny L ^k   Kote Jarai, Zsofia ^b   Easton, Douglas F ^c,g   Eyre, Steve ^a   Eeles, Rosalind A ^b,l  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d UNIVERSITY OF WARWICK   (United Kingdom)

^e CANCER EPIDEMIOLOGY CENTRE   (Australia)

^f UNIVERSITY OF MELBOURNE   (Australia)

^g UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^h CANCER RESEARCH UK CAMBRIDGE RESEARCH INSTITUTE   (United Kingdom)

ⁱ UNIVERSITY OF OXFORD   (United Kingdom)

^j UNIVERSITY OF OXFORD   (United Kingdom)

^k UNIVERSITY OF BRISTOL   (United Kingdom)

^l INSTITUTE OF CANCER RESEARCH   (United Kingdom)

more..

Author keywords

genetic variants; genome wide association studies (GWAS); prostate cancer; rheumatoid arthritis

Indexed keywords

HLA DRB1 ANTIGEN;

ARTICLE; AUTOIMMUNE DISEASE; AUTOSOME; CANCER RISK; CASE CONTROL STUDY; CCHCR1 GENE; CHROMOSOME 17Q; CHROMOSOME 3Q; CHROMOSOME 5P; COHORT ANALYSIS; CONTROLLED STUDY; GENE FREQUENCY; GENE LOCATION; GENE MAPPING; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC RISK; GENETIC VARIABILITY; GERM LINE; HLA DRB1 GENE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROSTATE CANCER; PUBLIC HEALTH; RHEUMATOID ARTHRITIS; SINGLE NUCLEOTIDE POLYMORPHISM;

ARTHRITIS, RHEUMATOID; AUSTRALIA; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; GREAT BRITAIN; HLA-DRB1 CHAINS; HUMANS; MALE; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; QUANTITATIVE TRAIT LOCI; REPRODUCIBILITY OF RESULTS;

EID: 84877709271     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2012.11492.x     Document Type: Article

References (56)

1. Cancer Research UK. CancerStats Key Facts; prostate cancer. 2011 [updated January 28, 2011]. Available at: http://info.cancerresearchuk.org/prod-consump/ groups/cr-common/@nre/@sta/documents/generalcontent/crukmig-1000ast-3088.pdf. Accessed 1 July 2011
2. Jemal A, Center MM, DeSantis C, Ward EM,. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 2010; 19: 1893-1907
3. The American Cancer Society. Prostate Cancer. 2007. Available at: http://www.cancer.org/acs/groups/content/@nho/documents/document/ prostatecancerpdf.pdf. Accessed 1 July 2011
4. Crawford ED,. Epidemiology of prostate cancer. Urology 2003; 62: (6 Suppl. 1): 3-12
5. Lichtenstein P, Holm NV, Verkasalo PK, et al. Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 2000; 343: 78-85
6. Schaid DJ,. The complex genetic epidemiology of prostate cancer. Hum Mol Genet 2004; 13 (Spec No 1): R103-121
7. Hemminki K, Vaittinen P,. Familial breast cancer in the family-cancer database. Int J Cancer 1998; 77: 386-391
8. Al Olama AA, Kote-Jarai Z, Giles GG, et al. Multiple loci on 8q24 associated with prostate cancer susceptibility. Nat Genet 2009; 41: 1058-1060
9. Amundadottir LT, Sulem P, Gudmundsson J, et al. A common variant associated with prostate cancer in European and African populations. Nat Genet 2006; 38: 652-658
10. Eeles RA, Kote-Jarai Z, Al Olama AA, et al. Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat Genet 2009; 41: 1116-1121
11. Eeles RA, Kote-Jarai Z, Giles GG, et al. Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet 2008; 40: 316-321
12. Gudmundsson J, Sulem P, Gudbjartsson DF, et al. Genome-wide association and replication studies identify four variants associated with prostate cancer susceptibility. Nat Genet 2009; 41: 1122-1126
13. Gudmundsson J, Sulem P, Manolescu A, et al. Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet 2007; 39: 631-637
14. Gudmundsson J, Sulem P, Rafnar T, et al. Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat Genet 2008; 40: 281-283
15. Gudmundsson J, Sulem P, Steinthorsdottir V, et al. Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat Genet 2007; 39: 977-983
16. Haiman CA, Chen GK, Blot WJ, et al. Genome-wide association study of prostate cancer in men of African ancestry identifies a susceptibility locus at 17q21. Nat Genet 2011; 43: 570-573
17. Kote-Jarai Z, Olama AA, Giles GG, et al. Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. Nat Genet 2011; 43: 785-791
18. Schumacher FR, Berndt SI, Siddiq A, et al. Genome-wide association study identifies new prostate cancer susceptibility loci. Hum Mol Genet 2011; 20: 3867-3875
19. Sun J, Zheng SL, Wiklund F, et al. Evidence for two independent prostate cancer risk-associated loci in the HNF1B gene at 17q12. Nat Genet 2008; 40: 1153-1155
20. Takata R, Akamatsu S, Kubo M, et al. Genome-wide association study identifies five new susceptibility loci for prostate cancer in the Japanese population. Nat Genet 2010; 42: 751-754
21. Thomas G, Jacobs KB, Yeager M, et al. Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet 2008; 40: 310-315
22. Yeager M, Orr N, Hayes RB, et al. Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet 2007; 39: 645-649
23. Duggan D, Zheng SL, Knowlton M, et al. Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. J Natl Cancer Inst 2007; 99: 1836-1844
24. Akamatsu S, Takata R, Haiman CA, et al. Common variants at 11q12, 10q26 and 3p11.2 are associated with prostate cancer susceptibility in Japanese. Nat Genet 2012; 44: 426-429
25. Demaria S, Pikarsky E, Karin M, et al. Cancer and inflammation: promise for biologic therapy. J Immunother 2010; 33: 335-351
26. Coussens LM, Werb Z,. Inflammation and cancer. Nature 2002; 420: 860-867
27. De Marzo AM, Platz EA, Sutcliffe S, et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007; 7: 256-269
28. De Nunzio C, Kramer G, Marberger M, et al. The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation. Eur Urol 2011; 60: 106-117
29. Davidsson S, Fiorentino M, Andren O, et al. Inflammation, focal atrophic lesions, and prostatic intra-epithelial neoplasia with respect to risk of lethal prostate cancer. Cancer Epidemiol Biomarkers Prev 2011; 20: 2280-2287
30. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363: 411-422
31. Hemminki K, Li X, Sundquist J, Sundquist K,. Cancer risks in Crohn disease patients. Ann Oncol 2009; 20: 574-580
32. Hemminki K, Li X, Sundquist J, Sundquist K,. Cancer risks in ulcerative colitis patients. Int J Cancer 2008; 123: 1417-1421
33. Chatterjee S, Dombi GW, Severson RK, Mayes MD,. Risk of malignancy in scleroderma: a population-based cohort study. Arthritis Rheum 2005; 52: 2415-2424
34. Rohekar S, Tom BD, Hassa A, Schentag CT, Farewell VT, Gladman DD,. Prevalence of malignancy in psoriatic arthritis. Arthritis Rheum 2008; 58: 82-87
35. Bernatsky S, Ramsey-Goldman R, Gordon C, Clarke AE,. Prostate cancer in systemic lupus erythematosus. Int J Cancer 2011; 129: 2966-2969
36. Parikh-Patel A, White RH, Allen M, Cress R,. Risk of cancer among rheumatoid arthritis patients in California. Cancer Causes Control 2009; 20: 1001-1010
37. Isaacs SD, Kiemeney LA, Baffoe-Bonnie A, Beaty TH, Walsh PC,. Risk of cancer in relatives of prostate cancer probands. J Natl Cancer Inst 1995; 87: 991-996
38. Goldgar DE, Easton DF, Cannon-Albright LA, Skolnick MH,. Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. J Natl Cancer Inst 1994; 86: 1600-1608
39. Cuzick J, Otto F, Baron JA, et al. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol 2009; 10: 501-507
40. Zheng SL, Liu W, Wiklund F, et al. A comprehensive association study for genes in inflammation pathway provides support for their roles in prostate cancer risk in the CAPS study. Prostate 2006; 66: 1556-1564
41. Freedman ML, Monteiro AN, Gayther SA, et al. Principles for the post-GWAS functional characterization of cancer risk loci. Nat Genet 2011; 43: 513-518
42. Bax M, van Heemst J, Huizinga TW, Toes RE,. Genetics of rheumatoid arthritis: what have we learned? Immunogenetics 2011; 63: 459-466
43. Gregersen PK,. Susceptibility genes for rheumatoid arthritis-a rapidly expanding harvest. Bull NYU Hosp Jt Dis 2010; 68: 179-182
44. Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007; 447: 661-678
45. MacGregor AJ, Bamber S, Silman AJ,. A comparison of the performance of different methods of disease classification for rheumatoid arthritis. Results of an analysis from a nationwide twin study. J Rheumatol 1994; 21: 1420-1426
46. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-324
47. Orozco G, Barton A, Eyre S, et al. HLA-DPB1-COL11A2 and three additional xMHC loci are independently associated with RA in a UK cohort. Genes Immun 2011; 12: 169-175
48. Hindroff LA, Junkins HA, Hall PN, Mehta JP, Manolio TA,. A Catalog of Published Genome-Wide Association Studies. 2009 [updated 21 July 2011]. Available at: http://www.genome.gov/gwastudies. Accessed 22 July 2011
49. COGS. Collaborative Oncological Gene-environment Study. 2009. Available at: http://www.cogseu.org/. Accessed 1 July 2011
50. Park JY, Huang Y, Sellers TA,. Single nucleotide polymorphisms in DNA repair genes and prostate cancer risk. Methods Mol Biol 2009; 471: 361-385
51. Goh CL, Schumacher FR, Easton D, et al. Genetic variants associated with predisposition to prostate cancer and potential clinical implications. J Intern Med 2012; 271: 353-365
52. Ewing CM, Ray AM, Lange EM, et al. Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med 2012; 366: 141-149
53. Bauer CM, Ray AM, Halstead-Nussloch BA, et al. Hereditary prostate cancer as a feature of Lynch syndrome. Fam Cancer 2011; 10: 37-42
54. Koyama A, Kubota Y, Shimamura T, Horiuchi S,. Possible association of the X-ray cross complementing gene 1 (XRCC1) Arg280His polymorphism as a risk for rheumatoid arthritis. Rheumatol Int 2006; 26: 749-751
55. Yosunkaya E, Karakurt F, Cetin E, et al. Rheumatoid arthritis risk associates with DNA repair gene XRCC1 Arg399Gln polymorphism in Turkish patients. Rheumatol Int 2012; 32: 1265-1269
56. Mechanic LE, Chen HS, Amos CI, et al. Next generation analytic tools for large scale genetic epidemiology studies of complex diseases. Genet Epidemiol 2012; 36: 22-35